EGFR and lung adenocarcinoma: This study demonstrates that high TMB is independently associated with poor progression-free and overall survivals, and a low frequency of secondary T790M mutation in patients with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma that are treated with tyrosine kinase inhibitors (TKIs).